Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: Preclinical characterization and phase I clinical trial

  1. Di Cosimo, S.
  2. Sathyanarayanan, S.
  3. Bendell, J.C.
  4. Cervantes, A.
  5. Stein, M.N.
  6. Braña, I.
  7. Roda, D.
  8. Haines, B.B.
  9. Zhang, T.
  10. Winter, C.G.
  11. Jha, S.
  12. Xu, Y.
  13. Frazier, J.
  14. Klinghoffer, R.A.
  15. Leighton-Swayze, A.
  16. Song, Y.
  17. Ebbinghaus, S.
  18. Baselga, J.
Revue:
Clinical Cancer Research

ISSN: 1557-3265,  1078-0432

Année de publication: 2015

Volumen: 21

Número: 1

Pages: 49-59

Type: Article

DOI: 10.1158/1078-0432.CCR-14-0940 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus